Eterna Therapeutics Inc.
ERNA
$-0.10
Change (1 day)
$2.63
Year High
$0.52
Year Low
Categories
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.
P/E ratio for Eterna Therapeutics Inc. (ERNA)
P/E ratio as of 2023: -0.44
According to Eterna Therapeutics Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.44. At the end of 2022 the company had a P/E ratio of -0.40.
P/E ratio history for Eterna Therapeutics Inc. from 2015 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -0.44 |
| 2022 | -0.40 |
| 2021 | -1.48 |
| 2020 | 3.31 |
| 2019 | -3.09 |
| 2018 | -20.24 |
| 2017 | -9.55 |
| 2016 | -5.53 |
| 2015 | -2.03 |